Kestra Medical Technologies Executive Sells Shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 24 2026
0mins
Source: Fool
- Transaction Overview: On June 15, 2026, Brian Daniel Webster reported the direct sale of 15,000 common shares of Kestra Medical Technologies, valued at $312,142.50 based on a weighted average purchase price of $20.81, leaving him with 395,467 shares worth approximately $8.07 million post-transaction.
- Historical Trading Pattern: This sale aligns with Webster's established trading pattern, as all seven of his sell transactions over the past year involved exactly 15,000 shares, indicating a consistent trading approach without significant escalation or reduction in volume.
- Holding Proportion Analysis: The transaction represented 3.65% of Webster's direct holdings, maintaining his substantial stake in Kestra Medical Technologies with 395,467 shares, thus not materially altering his exposure to the company.
- Company Performance Outlook: Kestra's latest quarterly report revealed revenue of $24.6 million, a 63% year-over-year increase, with gross margin expanding from 43.4% to 52.6%, and the fiscal 2026 revenue guidance raised to $93 million, indicating ongoing growth potential in market share and scale expansion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KMTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KMTS
Wall Street analysts forecast KMTS stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 27.880
Low
27.00
Averages
29.50
High
32.00
Current: 27.880
Low
27.00
Averages
29.50
High
32.00
About KMTS
Kestra Medical Technologies, Ltd. is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intelligent and connected. The Company has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The Company's Cardiac Recovery System platform includes ASSURE WCD, which is a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). Its Cardiac Recovery System platform also includes fully integrated digital solutions and services such as the ASSURE patient application, Kestra CareStation remote patient data platform, Heart Alert Services, and ASSURE Assist services and ASSURE wearable ECG.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kestra Medical Technologies Executive Sells Shares
- Transaction Overview: On June 15, 2026, Brian Daniel Webster reported the direct sale of 15,000 common shares of Kestra Medical Technologies, valued at $312,142.50 based on a weighted average purchase price of $20.81, leaving him with 395,467 shares worth approximately $8.07 million post-transaction.
- Historical Trading Pattern: This sale aligns with Webster's established trading pattern, as all seven of his sell transactions over the past year involved exactly 15,000 shares, indicating a consistent trading approach without significant escalation or reduction in volume.
- Holding Proportion Analysis: The transaction represented 3.65% of Webster's direct holdings, maintaining his substantial stake in Kestra Medical Technologies with 395,467 shares, thus not materially altering his exposure to the company.
- Company Performance Outlook: Kestra's latest quarterly report revealed revenue of $24.6 million, a 63% year-over-year increase, with gross margin expanding from 43.4% to 52.6%, and the fiscal 2026 revenue guidance raised to $93 million, indicating ongoing growth potential in market share and scale expansion.
See More
Webster Sells 15,000 Shares of Kestra Medical Technologies
- Transaction Overview: On June 15, 2026, Webster sold 15,000 shares of Kestra Medical Technologies for approximately $312,000, representing 3.65% of his direct holdings, reducing his ownership to 395,467 shares, indicating continued market engagement.
- Company Performance Growth: Kestra reported $24.6 million in revenue for the latest quarter, a 63% year-over-year increase, with gross margin rising from 43.4% to 52.6%, and raised its fiscal 2026 revenue guidance to $93 million, showcasing strong performance in the rapidly growing digital healthcare sector.
- Strategic Execution: Webster noted that Kestra is actively pursuing key operational goals, including expanding its commercial organization, strengthening its balance sheet, and promoting its ASSURE wearable defibrillator platform, which will help enhance market share in cardiovascular monitoring and intervention solutions.
- Market Outlook: While Webster's stock sale is viewed as routine, Kestra's accelerating commercial momentum and potential for market share expansion may be more appealing to long-term investors, especially as the company prioritizes growth over short-term profitability.
See More
Omega Fund Reduces Stake in Kestra Medical Technologies
- Stake Reduction Details: Omega Fund Management sold 351,442 shares of Kestra Medical Technologies in Q1 2026 for an estimated $8.28 million, indicating a cautious outlook on the company's future growth potential.
- Holding Proportion Change: Post-sale, Omega's stake in Kestra decreased to 12.5%, yet it remains a significant part of their reported AUM, suggesting ongoing confidence in the company's long-term prospects.
- Financial Performance Highlights: Kestra reported Q3 revenue of $24.6 million, a 63% year-over-year increase, with gross margin rising from 43.4% to 52.6%, indicating accelerating market acceptance of its products.
- Investment Mode and Challenges: Despite quarterly operating expenses surging to $47.7 million, resulting in a net loss of $34.2 million, Kestra's strong cash position of $291 million provides a buffer for future profitability efforts.
See More
Kestra Medical Technologies to Present at BofA Securities Healthcare Conference
- Conference Schedule: Kestra Medical Technologies is set to present at the BofA Securities 2026 Healthcare Conference on May 13 at 2:20 p.m. Pacific Time, showcasing its latest advancements in wearable medical devices, which is expected to attract attention from investors and industry experts.
- Company Overview: Kestra Medical Technologies focuses on transforming patient outcomes in cardiovascular disease through intuitive, intelligent, and connected monitoring and therapeutic intervention technologies, demonstrating its leadership in the digital healthcare sector and further solidifying its market share.
- Investor Relations: Interested parties can access the live webcast and replay of the presentation by visiting Kestra's investor relations website, enhancing engagement and transparency with investors while improving the company's image.
- Contact Information: Investors seeking further information can reach out to Neil Bhalodkar at neil.bhalodkar@kestramedical.com, ensuring timely access to relevant information and support.
See More
Director Raymond Cohen Increases Stake in Kestra Medical Technologies
- Share Purchase Details: On March 26, 2026, Director Raymond Cohen purchased 10,000 shares of Kestra Medical Technologies in an open market transaction valued at approximately $200,000, increasing his direct ownership from 40,903 to 50,903 shares, a 24.45% rise.
- Market Performance Analysis: As of April 2, 2026, Kestra Medical's stock price was $19.84, reflecting a 17.2% decline compared to the same period in 2025, indicating market challenges in the medical device sector, while Cohen's purchase may signal confidence in the company's future recovery.
- Transaction Context and Impact: Since joining the board in March 2025, Cohen has made two open-market purchases totaling 27,000 shares, demonstrating his ongoing commitment to the company's long-term growth, with this transaction executed without any indirect entities or derivative securities involved.
- Investor Focus Points: Cohen's extensive experience in the medical device industry, particularly his success with Axonics, may provide strategic insights for Kestra Medical's future, prompting investors to monitor contract wins and reimbursement coverage expansions closely.
See More
Director Raymond W. Cohen Increases Stake in Kestra Medical Technologies
- Share Acquisition: Director Raymond W. Cohen acquired 10,000 shares on March 26, 2026, for approximately $200,000, increasing his direct ownership by 24.45% to 50,903 shares, indicating confidence in the company's future prospects.
- Market Performance: The average purchase price for this acquisition was $19.98, while the post-transaction market close was $19.68, reflecting Cohen's investment strategy during a market downturn, potentially setting the stage for future price recovery.
- Industry Context: Kestra Medical focuses on advanced wearable solutions for cardiovascular risk management, and Cohen's extensive experience in the medical device sector will likely aid the company in navigating a competitive landscape.
- Investor Interest: Cohen's acquisition has sparked investor interest in the company's future contract wins, reimbursement coverage expansions, and patient base growth, especially given his low-price buying strategy, leading to heightened expectations for his subsequent actions.
See More
Kestra Medical Technologies Executive Sells Shares
- Transaction Overview: On June 15, 2026, Brian Daniel Webster reported the direct sale of 15,000 common shares of Kestra Medical Technologies, valued at $312,142.50 based on a weighted average purchase price of $20.81, leaving him with 395,467 shares worth approximately $8.07 million post-transaction.
- Historical Trading Pattern: This sale aligns with Webster's established trading pattern, as all seven of his sell transactions over the past year involved exactly 15,000 shares, indicating a consistent trading approach without significant escalation or reduction in volume.
- Holding Proportion Analysis: The transaction represented 3.65% of Webster's direct holdings, maintaining his substantial stake in Kestra Medical Technologies with 395,467 shares, thus not materially altering his exposure to the company.
- Company Performance Outlook: Kestra's latest quarterly report revealed revenue of $24.6 million, a 63% year-over-year increase, with gross margin expanding from 43.4% to 52.6%, and the fiscal 2026 revenue guidance raised to $93 million, indicating ongoing growth potential in market share and scale expansion.
See More
Webster Sells 15,000 Shares of Kestra Medical Technologies
- Transaction Overview: On June 15, 2026, Webster sold 15,000 shares of Kestra Medical Technologies for approximately $312,000, representing 3.65% of his direct holdings, reducing his ownership to 395,467 shares, indicating continued market engagement.
- Company Performance Growth: Kestra reported $24.6 million in revenue for the latest quarter, a 63% year-over-year increase, with gross margin rising from 43.4% to 52.6%, and raised its fiscal 2026 revenue guidance to $93 million, showcasing strong performance in the rapidly growing digital healthcare sector.
- Strategic Execution: Webster noted that Kestra is actively pursuing key operational goals, including expanding its commercial organization, strengthening its balance sheet, and promoting its ASSURE wearable defibrillator platform, which will help enhance market share in cardiovascular monitoring and intervention solutions.
- Market Outlook: While Webster's stock sale is viewed as routine, Kestra's accelerating commercial momentum and potential for market share expansion may be more appealing to long-term investors, especially as the company prioritizes growth over short-term profitability.
See More
Omega Fund Reduces Stake in Kestra Medical Technologies
- Stake Reduction Details: Omega Fund Management sold 351,442 shares of Kestra Medical Technologies in Q1 2026 for an estimated $8.28 million, indicating a cautious outlook on the company's future growth potential.
- Holding Proportion Change: Post-sale, Omega's stake in Kestra decreased to 12.5%, yet it remains a significant part of their reported AUM, suggesting ongoing confidence in the company's long-term prospects.
- Financial Performance Highlights: Kestra reported Q3 revenue of $24.6 million, a 63% year-over-year increase, with gross margin rising from 43.4% to 52.6%, indicating accelerating market acceptance of its products.
- Investment Mode and Challenges: Despite quarterly operating expenses surging to $47.7 million, resulting in a net loss of $34.2 million, Kestra's strong cash position of $291 million provides a buffer for future profitability efforts.
See More
Kestra Medical Technologies to Present at BofA Securities Healthcare Conference
- Conference Schedule: Kestra Medical Technologies is set to present at the BofA Securities 2026 Healthcare Conference on May 13 at 2:20 p.m. Pacific Time, showcasing its latest advancements in wearable medical devices, which is expected to attract attention from investors and industry experts.
- Company Overview: Kestra Medical Technologies focuses on transforming patient outcomes in cardiovascular disease through intuitive, intelligent, and connected monitoring and therapeutic intervention technologies, demonstrating its leadership in the digital healthcare sector and further solidifying its market share.
- Investor Relations: Interested parties can access the live webcast and replay of the presentation by visiting Kestra's investor relations website, enhancing engagement and transparency with investors while improving the company's image.
- Contact Information: Investors seeking further information can reach out to Neil Bhalodkar at neil.bhalodkar@kestramedical.com, ensuring timely access to relevant information and support.
See More
Director Raymond Cohen Increases Stake in Kestra Medical Technologies
- Share Purchase Details: On March 26, 2026, Director Raymond Cohen purchased 10,000 shares of Kestra Medical Technologies in an open market transaction valued at approximately $200,000, increasing his direct ownership from 40,903 to 50,903 shares, a 24.45% rise.
- Market Performance Analysis: As of April 2, 2026, Kestra Medical's stock price was $19.84, reflecting a 17.2% decline compared to the same period in 2025, indicating market challenges in the medical device sector, while Cohen's purchase may signal confidence in the company's future recovery.
- Transaction Context and Impact: Since joining the board in March 2025, Cohen has made two open-market purchases totaling 27,000 shares, demonstrating his ongoing commitment to the company's long-term growth, with this transaction executed without any indirect entities or derivative securities involved.
- Investor Focus Points: Cohen's extensive experience in the medical device industry, particularly his success with Axonics, may provide strategic insights for Kestra Medical's future, prompting investors to monitor contract wins and reimbursement coverage expansions closely.
See More
Director Raymond W. Cohen Increases Stake in Kestra Medical Technologies
- Share Acquisition: Director Raymond W. Cohen acquired 10,000 shares on March 26, 2026, for approximately $200,000, increasing his direct ownership by 24.45% to 50,903 shares, indicating confidence in the company's future prospects.
- Market Performance: The average purchase price for this acquisition was $19.98, while the post-transaction market close was $19.68, reflecting Cohen's investment strategy during a market downturn, potentially setting the stage for future price recovery.
- Industry Context: Kestra Medical focuses on advanced wearable solutions for cardiovascular risk management, and Cohen's extensive experience in the medical device sector will likely aid the company in navigating a competitive landscape.
- Investor Interest: Cohen's acquisition has sparked investor interest in the company's future contract wins, reimbursement coverage expansions, and patient base growth, especially given his low-price buying strategy, leading to heightened expectations for his subsequent actions.
See More
